2025-12-28 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics (TGTX) based on the data provided.

**0. Overview**

**TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.**

**1. Return Comparison**

*   **TGTX Cumulative Return:** 70.92%
*   **VOO (S&P 500) Cumulative Return:** 103.21%
*   **Divergence:** -28.8
*   **Relative Divergence:** 17.8

**Analysis:** TGTX has significantly underperformed the S&P 500 over the tracked period. The current divergence of -28.8 indicates that TGTX's cumulative return is currently 28.8 percentage points lower than the S&P 500.  The relative divergence of 17.8 suggests the divergence is closer to its minimum value compared to the maximum it has reached in the past.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | -5.0%  | 73.5% | -33.0%  | -0.0   | 1.3    |
| 2016-2018  | -12.0% | 73.5% | -27.0%  | -0.0   | 0.7    |
| 2017-2019  | 74.0%  | 74.1% | 52.0%   | 0.0    | 1.8    |
| 2018-2020  | 316.0% | 74.1% | 293.0%  | 0.1    | 8.3    |
| 2019-2021  | 124.0% | 74.1% | 78.0%   | 0.3    | 3.0    |
| 2020-2022  | -71.0% | 77.8% | -71.0%  | -0.0   | 1.9    |
| 2021-2023  | -284.0%| 77.8% | -285.0% | -1.1   | 2.7    |
| 2022-2024  | 56.0%  | 77.8% | 36.0%   | -1.0   | 4.8    |
| 2023-2025  | 71.0%  | 80.7% | 4.0%    | -0.1   | 4.9    |

*   **CAGR:**  Highly volatile, ranging from -284% to +316% showing wide year-to-year fluctuations
*   **MDD:** Consistently high Maximum Drawdown (MDD) values (around 73%-80%) indicate significant risk.
*   **Alpha:** Alpha is generally very high when the stock outperforms but becomes extremely negative when the stock underperforms.
*   **Beta:** Low Beta values (close to 0 or negative) suggest that the stock's price is not strongly correlated with the overall market. It indicates low or inverse correlation to the S&P 500.
*   **Cap(B):** Market capitalization, which fluctuated over the years, peaking in 2018-2020.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 30.77
*   **Previous Close:** 31.07
*   **Change:** -0.97
*   **5-day SMA:** 30.934
*   **20-day SMA:** 31.076
*   **60-day SMA:** 32.701

**Analysis:**  The stock price is currently slightly below its 5-day and 20-day moving averages and significantly below its 60-day moving average.  This suggests a short-term downward trend. The recent negative change indicates continued selling pressure.

**3. Indicators and Signals**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 50.07
*   **PPO:** 0.1629
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Divergence Change:** -0.5 (Short-term decline)
*   **Expected Return:** -126.8%

**Analysis:**

*   The MRI suggests a high investment recommendation, despite the other concerning factors. This might be misleading and should be viewed with caution.
*   RSI is neutral, indicating neither overbought nor oversold conditions.
*   PPO is also very close to 0, suggesting neither a strong positive or negative trend is in place.
*   The hybrid signal suggests buying, but the significantly negative expected return strongly contradicts this.
*   The negative recent divergence change supports the short-term downward trend.
*   The large negative Expected Return indicates very poor expected profitability.

**4. Recent News & Significant Events**

*   **[2025-10-31] Yahoo Finance:** "TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?" - Suggests mixed signals: recent weakness, but potentially strong financials.
*   **[2025-12-26] MarketBeat:** "TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Brokerages" - Indicates analyst optimism, but only moderate.
*   **[2025-11-03] Investor's Business Daily:** "The Earnings Caveat That Sent This Hot Biotech Diving" - Points to a specific negative event related to earnings.
*   **[2025-11-17] Seeking Alpha:** "TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX)" -  Suggests positive earnings, but increasing competitive pressures.
*   **[2025-11-19] Stock Titan:** "Deloitte Fast 500 names TG Therapeutics (NASDAQ: TGTX) among North Americaâ€™s fastest-growing firms" - Highlights rapid growth.
*   **[2025-12-19] Zacks Investment Research:** "Is the Options Market Predicting a Spike in TG Therapeutics Stock?" - Suggests potential for increased volatility.

**Analysis:** The news is mixed.  While some articles highlight growth and moderate buy recommendations, others point to recent weakness, negative earnings caveats, and increasing competition.  The options market potentially predicting a spike indicates uncertainty and potential for significant price movement.

**4-2. Analyst Opinions**

*   **Consensus:** Moderate Buy
*   **Target Price (avg/high/low):** 44.29 / 60.00 / 13.00

**Analysis:** Analyst consensus leans towards a "Moderate Buy".  The average target price of $44.29 represents a significant upside from the current price. However, the wide range between the high and low target prices ($60.00 vs. $13.00) suggests considerable disagreement among analysts regarding the stock's potential.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-11-05 | 2.69  | 0.16 B$      |
| 2025-08-08 | 0.19  | 0.14 B$      |
| 2025-05-09 | 0.03  | 0.12 B$      |
| 2024-11-07 | 0.03  | 0.08 B$      |
| 2025-11-05 | 0.03  | 0.08 B$      |

**Analysis:**

*   Earnings per share (EPS) showed a massive spike in the latest reporting period (2025-11-05). This could be due to a one-time event.
*   Revenue shows a generally increasing trend.

**6. Financial Information (Revenue, Profitability, Capital)**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.16B  | 82.63%        |
| 2025-06-30   | $0.14B  | 86.58%        |
| 2025-03-31   | $0.12B  | 87.14%        |
| 2024-12-31   | $0.11B  | 85.77%        |
| 2024-09-30   | $0.08B  | 88.86%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $0.61B    | 64.37%  |
| 2025-06-30   | $0.28B    | 10.20%  |
| 2025-03-31   | $0.24B    | 2.13%   |
| 2024-12-31   | $0.22B    | 10.49%  |
| 2024-09-30   | $0.19B    | 2.02%   |

**Analysis:**

*   **Revenue:** Shows a clear upward trend, indicating growth in sales.
*   **Profit Margin:** Consistently high profit margins suggest the company has strong pricing power and efficient cost management.
*   **Equity:** Increased significantly in the most recent quarter.
*   **ROE (Return on Equity):** A very high ROE in the latest quarter (64.37%) but inconsistent ROE values in prior quarters, likely influenced by the recent jump in profitability and equity changes. It is important to understand the driver of these changes to decide if they are sustainable.

**7. Comprehensive Analysis**

TG Therapeutics presents a mixed picture. Here's a summary:

*   **Negative Factors:**
    *   Significant underperformance compared to the S&P 500.
    *   High historical volatility (MDD) and negative Alpha in some periods.
    *   Short-term downward price trend based on moving averages.
    *   Very negative Expected Return.
    *   Recent news highlighting earnings caveats and increasing competition.
*   **Positive Factors:**
    *   Recent spike in EPS and upward trend in revenue.
    *   Consistently high profit margins.
    *   Deloitte Fast 500 recognition (fastest growing firms).
    *   Analyst consensus of "Moderate Buy" with a potentially significant upside target price (but with wide disagreement).

**Conclusion:**

Investing in TGTX appears highly risky. While the financial metrics and analyst ratings present some positive aspects, the significant underperformance compared to the S&P 500, the large potential downside indicated by the expected return, and concerning news events warrant caution. The company's financials showing growth in recent quarters are encouraging, but it is important to dive deeper into the driver of these changes to decide if they are sustainable.

**Recommendation:** Due to the conflicting signals, a high-risk tolerance is required. Consider a very small allocation with a strong understanding of the company's fundamentals and competitive landscape. Closely monitor news, earnings releases, and analyst updates.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.